New insights into bacterial persistence in reactive arthritis

Clinical and Experimental Rheumatology

Volumn 25, Issue 3, 2007, Pages 470-479

  Astrauskiene, Danute ^a   Bernotiene, Eiva ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Bacterial persistence; Biofilms; Cell wall deficient bacteria; L forms; Reactive arthritis

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; MACROLIDE; RIFAMPICIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERIUM DETECTION; BIOFILM; CHRONIC ARTHRITIS; DRUG TREATMENT FAILURE; HUMAN; LUNG INFECTION; MICROBIAL ACTIVITY; MICROBIAL MORPHOLOGY; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; PROTOPLAST; REACTIVE ARTHRITIS; REVIEW; RISK FACTOR; SPECIES DIFFERENTIATION; STONE FORMATION; STREPTOBACILLUS MONILIFORMIS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; ARTHRITIS, REACTIVE; BACTERIAL INFECTIONS; BIOFILMS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; L FORMS;

EID: 34447640194     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. GERARD HC, BRANIGAN PJ, SCHUMACHER HR Jr, HUDSON AP: Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol 1998; 25: 734-42.
2. GASTON JS, COX C, GRANFORS K: Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis. Arthritis Rheum 1999; 42: 2239-42.
3. YLI-KERTTULA T, LUUKKAINEN R, YLIKERTTULA U et al.: Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 2003; 62: 880-4.
4. SIEPER J, FENDLER C, LAITKO S et al.: No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum 1999; 42: 1386-96.
5. LAASILA K, LAASONEN L, LEIRISALOREPO M: Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 2003; 62: 655-8.
6. BEUTLER AM, HUDSON AP, WHITTUM-HUDSON JA et al.: Chlamydia trachomatis can persist in joint tissue after antibiotic treatment in chronic Reiter's syndrome/reactive arthritis. J Clin Rheumatol 1997; 3: 125-30.
7. DRESES-WERRINGLOER U, PADUBRIN I, JURGENS-SAATHOFF B, HUDSON AP, ZEIDLER H, KOHLER L: Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother 2000; 44: 3288-97.
8. ZHANG Y, GRIPENBERG-LERCHE C, SODERSTROM KO, TOIVANEN A, TOIVANEN P: Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. Arthritis Rheum 1996; 39: 1238-43
9. SCHWAB JH, BROWN RR, ANDERLE SK, SCHLIEVERT PM: Superantigen can reactivate bacterial cell-wall-induced arthritis. J Immunol 1993; 150: 4151-9.
10. ASTRAUSKIENIE D, BIŽANIENE G: Tonsillectomy can essentially improve the aggressive course of juvenile idiopathic arthritis. Acta medica Lituanica 2002; 9: 136-4.
11. DOMINGUE GJ Sr, WOODY HB: Bacterial persistence and expression of disease. Clin Microbiol Rev 1997; 10: 320-44.
12. VILLAREAL C, WHITTUM-HUDSON JA, HUDSON AP: Persistent Chlamydiae and chronic arthritis. Arthritis Res 2002; 4: 5-9.
13. KLIENEBERGER NE: The natural occurrence of pleuro-pneumonia-like organisms in apparent symbiosis with Streptobacillus moniliformis and other bacteria. J Pathol Bacteriol 1935; 40: 93-7.
14. MATTMAN LH: Stealth Pathogens, 3rd edn. Boca Raton, London, New York, Washington DC: CRC Press, 2001; 416.
15. GUMPERT J: Cellular growth without a murein sacculus - the nucleoid-associated compartmentation concept. In de PEDRO MA, HOLTJE JV, LOFFELHARDT W (Eds.): Bacterial growth and lysis. Metabolism and structure of the bacterial sacculus. New York, N Y Plenum Press 1992: 453-63.
16. ONODA T, ENOKIZONO J, KAYA H, OSHIMA A, FREESTONE P, NORRIS V: Effects of calcium and calcium chelators on growth and morphology of Escherichia coli L-form NC-7. J Bacteriol 2000; 182: 1419-22.
17. RHEN M, ERIKSSON S, CLEMENTS M, BERGSTROM S, NORMARK SJ: The basis of persistent bacterial infections. Trends Microbiol 2003; 11: 80-6.
18. BJORKHOLM B, ZHUKHOVITSKY V, LOFMAN C et al.: Helicobacter pylori entry into human gastric epithelial cells: A potential determinant of virulence, persistence, and treatment failures. Helicobacter 2000; 5: 148-54.
19. AMIEVA MR, SALAMA NR, TOMPKINS LS, FALKOW S: Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol 2002; 4: 677-90.
20. XU ZM, ZHOU DY, PAN L, SONG S: Transformation and reversion of Helicobacter pylori in vitro. Shijie Huaren Xiaohua Zazhi 1999; 7: 215-7.
21. WANG KX, LI CP, CUI YB, TIAN Y, YANG QG: L-forms of H.pylori. World J Gastroenterol 2003; 9: 525-8.
22. PIEPKORN MW, REICHENBACH DD: Infective endocarditis associated with cell wall-deficient bacteria. Electron microscopic findings in four cases. Hum Pathol 1978; 9: 163-73.
23. NASER SA, HULTEN K, SHAFRAN I, GRAHAM DY, EL-ZAATARI FA: Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis. Vet Microbiol 2000; 77: 497-504.
24. HULTEN K, KARTTUNEN TJ, EL-ZIMAITY HM et al.: In situ hybridization method for studies of cell wall deficient M. paratuberculosis in tissue samples. Vet Microbiol 2000; 77: 513-8.
25. MOSS MT, GREEN EP, TIZARD ML, MALIK ZP, HERMON-TAYLOR J: Specific detection of Mycobacterium paratuberculosis by DNA hybridisation with a fragment of the insertion element IS900. Gut 1991; 32: 395-8.
26. WANG H, CHEN Z: Observations of properties of the L-form of M. tuberculosis induced by the antituberculosis drugs. Zhonghua Jie He He Hu Xi Za Zhi 2001; 24: 52-5.
27. FLORES AE, FERRIERI P: The type-specific polysaccharide and the R protein antigens of the L-phase from a group B, type III Streptococcus. Zentralbl Bakteriol Mikrobiol Hyg (A) 1985; 259: 165-78.
28. ONWUAMAEGBU ME, BELCHER RA, SOARE C: Cell wall-deficient bacteria as a cause of infections: A review of the clinical significance. J Int Med Res 2005; 33: 1-20.
29. PHILLIPS SE, MATTMAN LH, HULINSKA D, MOAYAD H: A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated. Infection 1998; 26: 364-7.
30. LYNN RJ, HALLER GL: Bacterial L-forms as immunogenic agents. In GUZE LB (Ed.): Microbial protoplasts, spheroplasts and L-forms. Baltimore, Williams & Wilkins Co 1968: 270-8.
31. ELMER C, COOK P, NATTRESS F, CHEUNG P, FAWCETT T: Staphylococcus aureus cell wall-deficient bacteria are highly resistant to cell wall active antibiotics and have an altered profile to other classes of antibiotic. Thorax 2002; 57: Iii70.
32. TANG Y, WEN B, LI X, YAN XJ, GUO SJ: Using L-form bacterium ATP bioluminescence assay for rapid testing L-form bacterial susceptibility. Hunan Yi Ke Da Xue Xue Bao 2001; 26: 89-91.
33. IEŠMANTAITE NA: Biological characteristics and pathogenic potency of L-form Streptococci (Dissertation). Vilnius, Lithuania, Institute of Experimental and Clinical Medicine 1974, 241p. (Russian)
34. KAGAN CY, MIKHAILOVA VS: Isolation of L-forms of streptococci from the blood of patients with rheumatism and endocarditis. J Hyg Epidemiol Microbiol Immunol 1963; 13: 327-43.
35. NEWSOM SW: Staphylococcal persisters grown from empyema fluid on L-form medium. J Med Microbiol 1970; 3: 669-73.
36. CANTWELL AR, ROWE L, KELSO DW: Nodular scleroderma and pleomorphic acid-fast bacteria. Arch Dermatol 1980; 116: 1283-90.
37. HILL EO, LEWIS S: L forms of bacteria isolated from surgical infections. Bacteriol Proc 1964; 48: 1964-9.
38. ROSNER R: Isolation of protoplasts of Staphylococcus aureus from a case of recurrent acute osteomyelitis. Techn Bull Regist Med Technol 1968; 38: 205-10.
39. WOO PC, WONG SS, LUM PN, HUI WT, YUEN KY: Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. Lancet 2001; 357: 675-9.
40. SIMELYTE E, RIMPILAINEN M, RANTAKOKKO K et al.: Tissue distribution and persistence of arthritogenic and non-arthritogenic Eubacterium cell walls. Clin Exp Rheumatol 1999; 17: 281-8.
41. ZHANG X, RIMPILAINEN M, SIMELYTE E, TOIVANEN P: What determines arthritogenicity of bacterial cell wall? A study on Eubacterium cell wall-induced arthritis. Rheumatology (Oxford) 2000; 39: 274-82.
42. KAGAN GIA, VUL'FOVICH IUV, GUSMAN BS: Role of streptococcal L-forms in the pathogenesis of chronic infection and postinfection complications. Vestn Akad Med Nauk SSSR 1976; 5: 41-9.
43. KAGAN GY, PROZOROVSKY SV, KOPTELOVA EI et al.: Experimental angina of the monkey induced by L forms of group A streptococci. Ann Inst Pasteur (Paris) 1969; 116: 733-49.
44. COOK J, FINCHAM WJ, LACK CH: Chronic arthritis produced by streptococcal L-forms. J Pathol 1969; 99: 283-97.
45. MICHAILOVA L, MARKOVA N, RADOUCHEVA T, STOITSOVA S, KUSSOVSKI V, JORDANOVA M: Atypical behaviour and survival of Streptococcus pyogenes L forms during intraperitoneal infection in rats. FEMS Immunol Med Microbiol 2000; 28: 55-65.
46. TIMAKOV VD: The role of Mycoplasma and L-form bacteria in infectious diseases of man. Vestn Akad Med Nauk SSSR 1969; 24: 3-7.
47. KAGAN G, VULFOVITCH YU, GUSMAN B, RASKOVA T: Persistence and pathological effect of streptococcal L-forms in vivo. INSERM 1976; 65: 247-58.
48. KUNNAMO I: Infections and related risk factors of arthritis in children. A case-control study. Scand J Rheumatol 1987; 16: 93-9.
49. ASTRAUSKIENE D: Efficacy of empirically prescribed amoxicillin and amoxicillin + clavulanic acid in children's reactive arthritis: A randomised trial. Clin Exp Rheumatol 2003; 21: 515-2l.
50. EBRINGER A, WILSON C: HLA molecules, bacteria and autoimmunity. J Med Microbiol 2000; 49: 305-11.
51. EBRINGER R, COOKE D, CAWDELL DR, COWLING P, EBRINGER A: Ankylosing spondylitis: Klebsiella and HL-A B27. Rheumatol Rehabil 1977; 16: 190-6.
52. EBRINGER RW, CAWDELL DR, COWLING P, EBRINGER A: Sequential studies in ankylosing spondylitis. Association of Klebsiella pneumoniae with active disease. Ann Rheum Dis 1978; 37: 146-51.
53. ASTRAUSKIENE D: Some problems in revealing bacterial etiology of rheumatic arthritides in children. Acta Medica Lituanica 1995; 4: 77-84.
54. ASTRAUSKIENE D, RUTIENE K: Significant similarity of clinical features of Escherichia coli 01 triggered reactive arthritis in two teen-age girls. Scand J Rheumatol 2000; 29 (Suppl. 114): P71.
55. BAS S, GRIFFAIS R, KVIEN TK, GLENNAS A, MELBY K, VISCHER TL: Amplification of plasmid and chromosome Chamydia DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies. Arthritis Rheum 1995; 38: 1005-13.
56. SIEPER J, BRAUN J, KINGSLEY GH: Report on the Fourth International Workshop of Reactive Arthritis. Arthritis Rheum 2000; 43: 720-34.
57. SANIN AV, GONCHAROVA SA, SOSNOVSKAIA OIU, MERIMSKAIA OS, KOZHEVNIKOVA TN: Microorganism persistence in hematopoietiM tissue: means for detecting it and its significance. Zh Mikrobiol Epidemiol Immunobiol 1997; 4: 108-11.
58. SANIN AV, SOSNOVSKAIA OIU, GOLOVANOVA TA et al.: An immunological analysis of bacterial persistence in the bone marrow. Zh Mikrobiol Epidemiol Immunobiol 1994; 4 (Suppl. 1): 36-40.
59. COSTERTON JW, ATEWART PS, GREENBERG EP: Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
60. HALL-STOODLEY F, COSTERTON JW, STOODLEY P: Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2: 95-108.
61. McNAB R, FORD SK, EL-SABAENY A, BARBIERI B, COOK GS, LAMONT RJ: LuxS-based signaling in Streptococcus gordonii: Autoinducer 2 controls carbohydrate metabolism and biofilm formation with Porphyromonas gingivalis. J Bacteriol 2003; 185: 274-84.
62. LIU X, NG C, FERENCI T: Global adaptations resulting from high population densities in Escherichia coli cultures. J Bacteriol 2000; 182: 4158-64.
63. WENTLAND EJ, STEWART PS, HUANG CT, MCFETERS GA: Spatial variations in growth rate within Klebsiella pneumoniae colonies and biofilm. Biotechnol Prog 1996; 12: 316-21.
64. DAVIES DG, PARSEK MR, PEARSON JP, IGLEWSKI BH, COSTERTON JW, GREENBERG EP: The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998; 280: 295-8.
65. LAZAZZERA BA: Quorum sensSng and starvation: signals for entry into stationary phase. Curr Opin Microbiol 2000; 3: 177-82.
66. DAVIES DG, CHAKRABARTY AM, GEESEY GG: Exopolysaccharide production in biofilms: Substratum activation of alginate gene expression by Pseudomonas aeruginosa. Appl Environ Microbiol 1993; 59: 1181-6.
67. COSTERTON JW, LEWANDOWSKI Z, CALDWELL DE, KORBER DR, LAPPIN-SCOTT HM: Microbial biofilms. Annu Rev Microbiol 1995; 49: 711-45.
68. HIRAI Y, KAWAKATA N, SATOH K et al.: Concentrations of lactoferrin and iron in human milk at different stages of lactation. J Nutr Sci Vitaminol (Tokyo) 1990; 36: 531-44.
69. SINGH PK, PARSEK MR, GREENBERG EP, WELSH MJ: A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 552-5.
70. PROSSER BL, TAYLOR D, DIX BA, CLEELAND R: Method of evaluating effects of antibiotics on bacterial biofilm. Antimicrob Agents Chemother 1987; 31: 1502-6.
71. KORBER DR, JAMES GA, COSTERTON JW: Evaluation of fleroxacin activity against established Pseudomonas fluorescens biofilms. Appl Environ Microbiol 1994; 60: 1663-9.
72. ANDERL JN, FRANKLIN MJ, STEWART PS: Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2000; 44: 1818-24.
73. BROWN MR, ALLISON DG, GILBERT P: Resistance of bacterial biofilms to antibiotics: A growth-rate related effect? J Antimicrob Chemother 1988; 22: 777-80.
74. HAUSNER M, WUERTZ S: High rates of conjugation in bacterial biofilms as determined by quantitative in situ analysis. Appl Environ Microbiol 1999; 65: 3710-3.
75. GILBERT P, DAS J, FOLEY I: Biofilm susceptibility to antimicrobials. Adv Dent Res 1997; 11: 160-7.
76. MAIRA-LITRAN T, ALLISON DG, GILBERT P: Expression of the multiple antibiotic resistance operon (mar) during growth of Escherichia coli as a biofilm. J Appl Microbiol 2000; 88: 243-7.
77. MAH TF, O'TOOLE GA: Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-9.
78. KUCHMA SL, O'TOOLE GA: Surface induced and biofilm-induced changes in gene expression. Curr Opin Biotechnol 2000; 11: 429-33.
79. KIM HJ, JONES MN: The delivery of benzyl penicillin to Staphylococcus aureus biofilms by use of liposomes. J Liposome Res 2004; 14: 123-39.
80. LEWIS K: Riddle of biofilm resistance. Antimicrob Agents Chemother 2001; 45: 999-1007.
81. STEWART PS: New ways to stop biofilm infections. Lancet 2003; 361: 97.
82. COCHRAN WL, McFETERS GA, STEWART PS: Reduced susceptibility of thin Pseudomonas aeruginosa biofilms to hydrogen peroxide and monochloramine. J Appl Microbiol 2000; 88: 22-30.
83. YASUDA H, AJIKI Y, KOGA T, KAWADA H, YOKOTA T: Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother 1993; 37: 1749-55.
84. SUNTHARALINGAM P, CVITKOVITCH DG: Quorum sensing in streptococcal biofilm formation. Trends Microbiol 2005; 13: 3-6.
85. HENTZER M, RIEDEL K, RASMUSSEN TB et al.: Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 2002; 148: 87-102.
86. DONLSN RM, COSTERTON JW: Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
87. FINELLI A, GALLANT CV, JARVI K, BURROWS LL: Use of in-biofilm expression technology to identify genes involved in Pseudomonas aeruginosa biofilm development. J Bacteriol 2003; 185: 2700-10.
88. WARD KH, OLSON ME, LAM K, COSTERTON JW: Mechanism of persistent infection associated with peritoneal implants. J Med Microbiol 1992; 36: 406-13.
89. COCHRANE DM, BROWN MR, ANWAR H, WELLER PH, LAM K, COSTERTON JW: Antibody response to Pseudomonas aeruginosa surface protein antigens in a rat model of chronic lung infection. J Med Microbiol 1988; 27: 255-61.
90. RIOUFOL C, DEVYS C, MEUNIER G, PERRAUD M, GOULLET D: Quantitative determination of endotoxins released by bacterial biofilms. J Hosp Infect 1999; 43: 203-9.
91. RAYNER MG, ZHANG Y, GORRY MC, CHEN Y, POST JC, EHRLICH GD: Evidence of bacterial metabolic activity in culture-negative otitis media with effusion. JAMA 1998; 279: 296-9.
92. TUNNEY MM, PATRICK S, CURRAN MD et al.: Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol 1999; 37: 3281-90.
93. PRESTERL E, GRISOLD AJ, REICHMANN S, HIRSCHL AM, GEORGOPOULOS A, GRANINGER W: Viridans streptococci in endocarditis and neutropenic sepsis: Biofilm formation and effects of antibiotics. J Antimicrob Chemother 2005; 55: 45-50.
94. RAJAN S, SAIMAN L: Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002; 17: 47-56.
95. MURPHY TF, KIRKHAM C: Biofilm formation by nontypeable Haemophilus influenzae: Strain variability, outer membrane antigen expression and role of pili. BMC Microbiol 2002; 2: 7.
96. MARRIE TJ, COSTERTON JW: Mode of growth of bacterial pathogens in chronic polymicrobial human osteomyelitis. J Clin Microbiol 1985; 22: 924-33.
97. LAI CW, CHAN RC, CHANG AF, SUNG JY, LEUNG JW: Common bile duct stones: a cause of chronic salmonellosis. Am J Gastroenterol 1992; 87: 1198-9.
98. PROUTY AM, SCHWESINGER WH, GUNN JS: Biofilm formation and interaction with the surfaces of gallstones by Salmonella spp. Infect Immun 2002; 70: 2640-9.
99. NICKEL JC, OLSON M, McLEAN RJ, GRANT SK, COSTERTON JW: An ecological study of infected urinary stone genesis in an animal model. Br J Urol 1987; 59: 21-30.
100. BERGER RE, KRIEGER JN, ROTHMAN I, MULLER CH, HILLIER SL: Bacteria in the prostate tissue of men with idiopathic prostatic inflammation. J Urol 1997; 157: 863-5.
101. YOKOI N, OKADA K, SUGITA J, KINOSHITA S: Acute conjunctivitis associated with biofilm formation on a punctal plug. Jpn J Ophthalmol 2000; 44: 559-60.
102. SWIDSINSKY A, SCHLIEN P, PERNTHALER A et al.: Bacterial biofilms within diseased pancreatic and biliary tracts. Gut 2005; 54: 388-95.
103. KLIN B, BOLDUR I, HALEVY A, BARR J, VINOGRAD I: Bacteriology of cholelithiasis in infants and children. Surg Laparosc Endosc 1997; 7: 137-9.
104. PAPADOPOULOU F, EFREMIDIS S, KARYDA S et al.: Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr 1999; 88: 1352-5.
105. BONNET JP, ABID L, DABHAR A, LEVY A, SOULIER Y, BLANGY S: Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: A prospective study in 34 children. Eur J Pediatr Surg 2000; 10: 368-71.
106. HEREK O, PAKDEMIRLI E, KOCER N: Ceftriaxone-associated biliary pseudolithiasis in children. Eur Radiol 2001; 11: 902.
107. JOSHUA GW, KARLYSHEV AV, SMITH MP, ISHERWOOD KE, TITBALL RW, WREN BW: A Caenorhabditis elegans model of Yersinia infection: Biofilm formation on a biotic surface. Microbiology 2003; 149(Pt 11): 3221-9.
108. MCAULIFFE L, ELLIS RJ, MILES K, AYLING RD, NICHOLAS RA: Biofilm formation by mycoplasma species and its role in environmental persistence and survival. Microbiology 2006; 152(Pt 4): 913-22.
109. ANDERL JN, ZAHLLER J, ROE F, STEWART PS: Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2003; 47: 1251-6.
110. ZAHLLER J, STEWART PS: Transmission electron microscopic study of antibiotic action on Klebsiella pneumoniae biofilm. Antimicrob Agents Chemother 2002; 46: 2679-83.
111. GUERCINI F, PAJONCINI C, BARD R et al.: Echoguided drug infiltration in chronic prostatitis: Results of a multi-centre study. Arch Ital Urol Androl 2005; 77: 87-92.
112. DEIGHTON C: Beta haemolytic streptococci and reactive arthritis in adults. Ann Rheum Dis 1993; 52: 475-82.
113. AHMED S, AYOUB EM, SCORNIK JC, WANG CY, SHE JX: Poststreptococcal reactive arthritis: Clinical characteristics and association with HLA-DR alleles. Arthritis Rheum 1998; 41: 1096-102.
114. ALEXOPOULOU A, DOURAKIS SP, STAMOULIS ND, VASSILOPOULOS D, ARCHIMANDRITIS AJ: Poststreptococcal reactive arthritis with thoracic spine involvement in an adult. J Rheumatol 2005; 32: 2002-5.
115. KUHN SM, PREIKSAITIS JK, TYRRELL GJ, JADAVJI T, CHURCH D, DAVIES HD: Evaluation of potential factors contributing to microbiologic treatment failure in Streptococcus pyogenes pharyngitis. Can J Infect Dis 2001; 12: 33-9.
116. BISNO AL, GERBER MA, GWALTNEY JM Jr, KAPLAN EL, SCHWARTZ RH: Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002; 35: 113-25.
117. CONLEY J, OLSON ME, COOK LS, CERI H, PHAN V, DAVIES HD: Biofilm formation by group A streptococci: Is there a relationship with treatment failure? J Clin Microbiol 2003; 41: 4043-8.
118. CHOLE RA, FADDIS BT: Anatomical evidence of microbial biofilms in tonsillar tissues: A possible mechanism to explain chronicity. Arch Otolaryngol Head Neck Surg 2003; 129: 634-6.
119. LEMBKE C, PODBIELSKI A, HIDALGO-GRASS C, JONAS L, HANSKI E, KREIKEMEYER B: Characterization of biofilm formation by clinically relevant serotypes of group A streptococci. Appl Environ Microbiol 2006; 72: 2864-75.
120. CIMAZ R, MEREGALLI E, BIGGIOGGERO M, CASADEI A, CAREDDU P: Arthritis and infections. Minerva Pediatr 2005; 57: 181-8.
121. EHRLICH GD, VEEH R, WANG X et al.: Mucosal biofilm formation on middle-ear mucosa in the chinchilla model of otitis media. JAMA 2002; 287: 1710-5.
122. POST JC: Direct evidence of bacterial biofilms in otitis media. Laryngoscope 2001; 111: 2083-94.
123. BUDHANI RK, STRUTHERS JK: Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: Investigation of the indirect pathogenic role of beta-lactamase-producing Moraxellae by use of a continuous-culture biofilm system. Antimicrob Agents Chemother 1998; 42: 2521-6.
124. TRAMPUZ A, ZIMMERLI W: New strategies for the treatment of infections associated with prosthetic joints. Curr Opin Investig Drugs 2005; 6: 185-90.
125. TRAMPUZ A, WIDMER AF: Infections associated with orthopedic implants. Curr Opin Infect Dis 2006; 19: 349-56.
126. SAGINUR R, DENIS M ST, FERRIS W et al.: Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006; 50: 55-61.
127. AMERICAN THORACIC SOCIETY/CENTERS FOR DISEASE CONTROL AND PREVENTION/ INFECTIOUS DISEASES SOCIETY OF AMERICA: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
128. CHAISSON RE: Treatment of chronic infectionI with rifamycins: is resistance likely to follow? Antimicrob Agents Chemother 2003; 47: 3037-9.
129. SVENSSON E, HANBERGER H, NILSSON LE: Pharmacodynamic effects of antibiotics and antibiotic combinations on growing and nongrowing Staphylococcus epidermidis cells. Antimicrob Agents Chemother 1997; 41: 107-11.
130. SLINGER R, CHAN F, FERRIS W et al.: Multiple combination antibiotic susceptibility testing of nontypeable Haemophilus influenzae biofilms. Diagn Microbiol Infect Dis 2006; 56: 247-53.
131. CARTER JD, VALERIANO J, VASEY FB: Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol 2004; 31: 1973-80.
132. AOKI S: Are enterobacterial common antigens involved in the etiology of rheumatoid arthritis? Clin Exp Rheumatol 2005; 23: 285-8.
133. STOODLEY P, SAUER K, DAVIES DG, COSTERTON JW: Biofilms as complex diferentiated communities. Annu Rev Microbiol 2002; 56: 187-209.
134. HIBMA AM, JASSIM SA, GRIFFITHS MW: In vivo bioluminescence to detect the attachment of L-forms of Listeria monocytogenes to food and clinical contact surfaces. Int J Food Microbiol 1996; 33: 157-67.
135. HIBMA AM, JASSIM SA, GRIFFITHS MW: Infection and removal of L-forms of Listeria monocytogenes with bred bacteriophage. Int J Food Microbiol 1997; 34: 197-207.